JP2022541667A5 - - Google Patents

Info

Publication number
JP2022541667A5
JP2022541667A5 JP2022505447A JP2022505447A JP2022541667A5 JP 2022541667 A5 JP2022541667 A5 JP 2022541667A5 JP 2022505447 A JP2022505447 A JP 2022505447A JP 2022505447 A JP2022505447 A JP 2022505447A JP 2022541667 A5 JP2022541667 A5 JP 2022541667A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
tautomer
solvate
pharmaceutical composition
adenosine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022505447A
Other languages
English (en)
Japanese (ja)
Other versions
JP7700096B2 (ja
JP2022541667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043713 external-priority patent/WO2021021717A1/en
Publication of JP2022541667A publication Critical patent/JP2022541667A/ja
Publication of JP2022541667A5 publication Critical patent/JP2022541667A5/ja
Application granted granted Critical
Publication of JP7700096B2 publication Critical patent/JP7700096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022505447A 2019-07-27 2020-07-27 アデノシン誘導体及びそれを含む薬学的組成物 Active JP7700096B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879414P 2019-07-27 2019-07-27
US62/879,414 2019-07-27
PCT/US2020/043713 WO2021021717A1 (en) 2019-07-27 2020-07-27 Adenosine derivative and pharmaceutical composition comprising the same

Publications (3)

Publication Number Publication Date
JP2022541667A JP2022541667A (ja) 2022-09-26
JP2022541667A5 true JP2022541667A5 (cg-RX-API-DMAC7.html) 2023-08-07
JP7700096B2 JP7700096B2 (ja) 2025-06-30

Family

ID=74229552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505447A Active JP7700096B2 (ja) 2019-07-27 2020-07-27 アデノシン誘導体及びそれを含む薬学的組成物

Country Status (12)

Country Link
US (2) US12370208B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003369A4 (cg-RX-API-DMAC7.html)
JP (1) JP7700096B2 (cg-RX-API-DMAC7.html)
KR (1) KR102994676B1 (cg-RX-API-DMAC7.html)
CN (1) CN114502175B (cg-RX-API-DMAC7.html)
AU (1) AU2020320876B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000965A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146679A1 (cg-RX-API-DMAC7.html)
IL (1) IL289925B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022000563A (cg-RX-API-DMAC7.html)
TW (1) TWI862645B (cg-RX-API-DMAC7.html)
WO (1) WO2021021717A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310695B (zh) 2016-04-21 2022-04-01 阿斯特罗赛特制药公司 治疗神经和心血管病况的化合物和方法
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
KR20220132608A (ko) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
US20240368164A1 (en) * 2021-04-28 2024-11-07 Astrocyle Pharmaceuticals, Inc. Purine nucleosides, their intermediates, and methods of preparation thereof
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
EP4658663A2 (en) 2023-01-30 2025-12-10 Merck Sharp & Dohme LLC Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
TW202500140A (zh) * 2023-06-27 2025-01-01 美商基利科學股份有限公司 製備抗病毒前藥之方法及中間物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EP1915053A2 (en) 2005-08-12 2008-04-30 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
US20160199396A1 (en) 2013-08-29 2016-07-14 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20180030080A1 (en) 2016-07-28 2018-02-01 Alexandre Vasilievich Ivachtchenko Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use
US10266558B2 (en) 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
EP3558322B1 (en) 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
US11337964B2 (en) 2017-02-28 2022-05-24 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, pharmaceutical composition and use thereof
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
US10676252B2 (en) * 2017-12-21 2020-06-09 Helen Of Troy Limited Container with sealable lid
DE102018200487A1 (de) * 2018-01-12 2019-07-18 Knorr-Bremse Systeme für Schienenfahrzeuge GmbH Vorrichtung und Verfahren zur Realisierung kontrollierter Reaktionen bei einer Systemstörung
CN109053803A (zh) 2018-07-04 2018-12-21 米文君 一类新的化合物及其用途
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US20210323993A1 (en) * 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
WO2021038509A1 (en) 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
WO2021260641A1 (en) 2020-06-27 2021-12-30 Laurus Labs Limited Oral film of hiv drugs
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
WO2023196832A2 (en) 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Similar Documents

Publication Publication Date Title
JP2024503723A5 (cg-RX-API-DMAC7.html)
KR100509130B1 (ko) 친지성 화합물의 자가유화 제제
JP2016509047A5 (cg-RX-API-DMAC7.html)
RU2662819C2 (ru) Твердая дисперсия с улучшенной растворимостью, содержащая производное тетразола в качестве активного ингредиента
CA2805206A1 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
JPS5995269A (ja) 抗てんかん性医薬品
UA120508C2 (uk) Комплекси сиролімусу і його похідних, спосіб їх отримання і фармацевтичні композиції, що містять зазначені комплекси
CN113747896A (zh) 来那度胺和其他免疫调节剂的连续递送
KR101767296B1 (ko) 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제
ES2384333T3 (es) Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles
JP2020511437A5 (cg-RX-API-DMAC7.html)
JP2017505313A5 (cg-RX-API-DMAC7.html)
CN103012438B (zh) 烷氧基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
CN102196810B (zh) 改善肠吸收性的药物组合物
RU2022104985A (ru) Аденозиновое производное и фармацевтическая композиция, содержащая его
JP5936609B2 (ja) キナーゼインヒビターの経口製剤
WO2014015153A2 (en) Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
WO2005051368A2 (en) Phosphodiesterase v inhibitor formulations
JPH10503178A (ja) Hiv感染のための組合わせ療法
KR101118199B1 (ko) 타크롤리무스를 가용화하기 위한 고분자 미셀 조성물
EA010293B1 (ru) Частицеобразующие композиции, содержащие конденсированные пирролокарбазолы
JP2008208122A (ja) 肥満の予防及び/又は治療薬
JP4598674B2 (ja) 統合失調症治療剤
KR20260057626A (ko) 프탈라지논 화합물 및 이의 제조 방법, 약학 조성물 및 용도
RU2022105060A (ru) Производные дигидропиримидина и пути их применения в лечении инфекции, вызываемой hbv, или заболеваний, вызываемых hbv